Our team

Operating Advisory Board

Raj Airey

Strategic Advisor

Raj is a venture developer, advisor and investor in early stage biotech and medical device businesses with extensive experience in the health sector and senior leadership roles with blue chip firms like Pfizer and Baxter.

He is also an entrepreneur, having founded several companies and exited two in the healthcare space. He has also been involved in many fund raising and licensing deals across the globe.

Raj founded Wizzcare Home Health Solutions, a pioneer in home care and tele-health company in India, which was sold to Indian’s leading E-health business. He is also a co-founder of Health Start, India’s first Healthcare accelerator. The accelerator has invested extensively in portfolio health companies, and Raj is an active board member and mentor to some of them.

He is a post graduate from the London University and executive programs from Harvard Business School and INSEAD, as well as an Accredited Executive Coach of the International Coaching Federation.

Lídia Casas

Patent Attorney

Lídia has a degree in Biochemistry and she is Qualified European Patent Attorney (EQE-2014). She is a professional with 15 years experience in Intellectual Property, especially in the fields of biotechnology and biomedicine. She has held different positions at a university technology transfer office, at a law firm working as patent advisor, in the private sector working as chief IP officer and as a professor in this area. She has gained experience and knowledge in all technical aspects related to patents (e.g. state of the art analysis, patentability and freedom-to-operate reports, patent drafting, patent prosecution, due dilligence) but also in the management of patent portfolios, patent lifecycle and in defining strategies aligned with company's business and research. Besides her knowledge of the European patent system, her knowledge in patent systems of around 20 different countries gives her a global vision. She has recently created her own project of patent consultancy, Patent Riders. Lídia works for Ability Pharmaceuticals as external IP Manager, managing all the aspects of IP of the company.  

Esperanza Regueras

Market Research and Strategy Advisor

Esperanza Regueras obtained a degree in Pharmacy at Univerity of Navarra in Pamplona and a MBA at IESE business school in Barcelona. For more than 8 years she has worked as employee in pharmaceutical companies in a multinational environment. In 2004, following its entrepreneurship instints, she founded Axis Pharma firm, specialized in strategic consulting and market research services for pharmaceutical companies worldwide. Axis Pharma has provided its services to more than 20 big multinationals and has helped many biotech companies and R&D groups. Its large experience in a such a innovative sector has provided to her a deep background in innovation and improvement.

Albert Martínez

Legal Advisor

Albert holds a Bachelor of Law degree (University of Barcelona, Spain) and also a Juris Doctor of Law degree (accredited by The American Bar Association, USA). He has been a member of the Barcelona Bar Association for more than 10 years and he specializes in Intellectual Property rights, as well as innovation and entrepreneurship, focusing on the Life Sciences and Healthcare. He regularly advises companies in the technological and biotechnological sector, mainly in the area of research and development, as well as in the protection, exploitation and transfer of their technology. He also has extensive experience in litigation and transactions relating to patents, designs, trademarks, trade secrets, know-how and unfair competition. Albert is involved in many technological companies as an external legal advisor. 

Sara Secall

Sara holds a BS in Chemistry, MSc from Indiana University and an MBA from the London Business School. She is currently the Investment Director of Inveready. Prior to joining Inveready, as Director of Spin Outs for the University of Barcelona, she was involved in starting and financing over 25 technology start ups and she negotiated numerous technology licenses, mainly in the biotechnology sector. She has worked extensively in the USA, Latin America and Europe. She is responsible for building the Biotech Portfolio and sits at the board of Avizorex, Agrasys, Innoup Pharma, Oncostellae, ZIP Solutions and Minoryx.
 

Roger Torrent

Roger Torrent obtained his Chemical Engineering Degree at the Institut Quimic de Sarrià (IQS), Barcelona, and he is currently Senior Consultant for national and international public aids. He joined Inveready in 2012 and his work focuses on identifying, preparing and monitoring public funding for innovative business projects, and R&D lines, both nationally and internationally.
 
Previously, he worked as a grant manager for 4 years at the biotechnology firm AB-Biotics, a probiotics and pharmacogenetics company in the field of neurospiquiatría, obtaining financing for the development of their projects, and accompanying it from its initial stages until the exit to the alternative stock market. He has also worked as a consultant in the Euro-Funding firm, specialized in obtaining public funds for business development projects.

LATEST NEWS

05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits